Xencor Appoints Yujiro S. Hata to Board of Directors

MONROVIA, Calif., July 31, 2015 -- (Healthcare Sales & Marketing Network) -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases... Biopharmaceuticals, PersonnelXencor, monoclonal antibody

Source: HSMN NewsFeed - July 31, 2015 Category: Pharmaceuticals Source Type: news